美国可治愈乳腺癌治疗中的地理空间差异
该回顾性人群队列研究基于SEER-Medicare数据库纳入31571例I-III期乳腺癌患者,分析5项初始治疗指标的地理空间差异。结果显示,区域/健康服务区解释的变异(24%-48%)远大于患者因素(1%-4%),而最大比例变异未被解释(35%-54%)。作者认为未来质量改进应聚焦减少不必要的地理空间差异,尤其在低绩效区域优化内分泌治疗的实施。
要点
- 区域/健康服务区解释的变异为24%-48%,患者因素仅1%-4%,未解释变异占35%-54%。
- 内分泌治疗启动和持续中区域/健康服务区解释的变异比例最大,分别为28%和39%。
- 作者建议未来质量改进应聚焦减少不必要的地理空间差异,尤其优化低绩效区域的内分泌治疗实施。
核心结论
- 该队列研究中,初始乳腺癌治疗存在大量未解释的地理空间差异,区域/健康服务区解释的变异远大于患者因素。
- 作者认为未来质量改进应聚焦减少不必要的地理空间差异,尤其包括优化低绩效区域的内分泌治疗实施。
研究设计与样本
- 回顾性人群队列研究,使用监测、流行病学和最终结果(SEER)-Medicare数据库,纳入2007年至2013年诊断为I-III期乳腺癌的31571例患者。
- 研究覆盖2007年1月1日至2016年12月31日,数据分析于2021年1月至6月进行。
- 采用分层多变量模型将各指标的总变异按比例归因于随机、患者因素、区域(健康服务区[HSA])和未解释四个域。
主要发现
- 31571例患者中位(IQR)年龄为71(68-75)岁,19391例(61.4%)诊断时为I期。
- 符合条件患者中,21190例中17297例(81.6%)接受放疗,9903例中7204例(72.8%)接受化疗,26855例中13115例(48.8%)启动内分泌治疗,26855例中13944例(52.1%)持续内分泌治疗。
- 全部5项指标中,区域/健康服务区解释的变异(24%-48%)大于患者因素(1%-4%),未解释变异占比最大(35%-54%)。
- 区域/健康服务区解释变异比例最大的指标为内分泌治疗启动和持续,分别为28%和39%。
临床怎么用
- 原文结论未据此给出具体临床推荐,仅指出未来质量改进应聚焦减少不必要的地理空间差异,尤其包括优化低绩效区域的内分泌治疗实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patient factors help explain disparities in breast cancer treatments and outcomes. OBJECTIVE: To determine the extent to which geospatial variation in initial breast cancer care can be attributed to region vs patient factors with the aim of guiding quality improvement efforts. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective population-based cohort study from January 1, 2007, through December 31, 2016, using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database that included 31 571 patients diagnosed with stage I to III breast cancer from 2007 through 2013. Five metrics of care delivery were defined: stage I at diagnosis, chemotherapy receipt, radiation therapy receipt, endocrine therapy (ET) initiation (year 1), and ET continuation (years 3-5). Data analysis was performed from January to June 2021. EXPOSURES: Stage I diagnosis and treatment with chemotherapy, radiation therapy, or ET. MAIN OUTCOMES AND MEASURES: For each metric, total variance was attributed proportionally to 4 domains-random, patient factors (eg, age, race and ethnicity, socioeconomic status), region (health service area [HSA]), and unexplained-using hierarchical multivariable modeling. RESULTS: Of 31 571 total patients (median [IQR] age, 71 [68-75] years), 19 391 (61.4%) had stage I disease at diagnosis. Among eligible patients, 17 297 of 21 190 (81.6%) received radiation therapy, 7204 of 9903 (72.8%) received chemotherapy, 13 115 of 26 855 (48.8%) initiated ET, and 13 944 of 26 855 (52.1%) continued ET. Geospatial density (ie, heat) maps highlight regional performance patterns. For all 5 metrics, region/HSA explained more observed variation (24%-48%) than patient factors (1%-4%); the largest share of variation was unexplained (35%-54%). The metrics with the largest proportion of total variance attributed to region/HSA were ET initiation and continuation (28% and 39%, respectively). CONCLUSIONS AND RELEVANCE: In this cohort study, there was substantial unexplained geospatial variation in initial breast cancer care. The variance attributed to region/HSA was multifold larger than that explained by patient factors. The importance of patient factors such as race and ethnicity notwithstanding, future quality improvement efforts should focus on reducing unwarranted geospatial variation, especially including optimizing the delivery of ET in low-performing regions.
引用
- Hassett MJ, Tramontano AC, Uno H, et al. Geospatial Disparities in the Treatment of Curable Breast Cancer Across the US. JAMA Oncol. 2022. PMID: 35084444. doi:10.1001/jamaoncol.2021.7337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。